Form D · Biotechnology
Surrozen, Inc./DE
South San Francisco, CA · CIK 0001824893
Offering snapshot reported Apr 8, 2025 · SEC filing
- Reported sold
- $76.4M Offering amount: $175M
- Investors reported
- 29 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 26, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 8, 2025 | Initial | $76,402,277 | No comparison | 29 | SEC filing |
| Apr 19, 2024 | Initial | $193,015,962 | No comparison | 18 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $4.58M
- Finders' fees
- $0
- Form D file number
- 021-543181
The Company issued to investors units, each consisting of one share of common stock, or pre-funded warrant in lieu thereof, and one half of a common stock warrant.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Guggenheim Securities, LLC | 40638 |
Source: Form D, filed Apr 8, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Anna Berkenblit, M.D. | Director |
| Eric Bjerkholt | Director |
| Christopher Chai | Director |
| Mary Haak Frendscho, Ph.D. | Director |
| Tim Kutzkey, Ph.D. | Director |
| Shao Lee Lin, M.D., Ph.D. | Director |
| Yang Li, Ph.D. | Executive |
| Craig Parker | Director, Executive |
| Mace Rothenberg, M.D. | Director |
| Charles Williams | Executive |
| David J. Woodhouse, Ph.D. | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
171 Oyster Point Blvd Suite 400
South San Francisco, CA, 94080
South San Francisco, CA, 94080